MADRID, June 23, 2017 /PRNewswire/ --
Cerdulatinib is an oral, dual Syk-JAK inhibitor with a unique mechanism of action. It inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies: the B-cell receptor pathway via Syk and key cytokine receptors via JAK. Preclinical data suggested that cerdulatinib may have anti-tumor activity in patients who did not adequately respond to, or relapsed on, other treatments due to defined mutations.
(Logo: http://mma.prnewswire.com/media/524821/EHA_Logo.jpg )
The current study is evaluating the safety and efficacy of cerdulatinib in patients with certain types of non-Hodgkin Lymphoma. Up to 40 patients each will be enrolled in cohorts including patients with relapsed/refractory chronic lymphocytic leukemia (CLL), and indolent lymphomas such as follicular lymphoma (FL) and peripheral T cell lymphoma (PTCL).
The interim results presented at this meeting demonstrated evidence of differentiated clinical activity in patients with relapsed/refractory B-cell malignancies. To date, overall response rates are as follows:
- 12 out of 18 (67%) partial responses (PRs) in patients with r/r CLL/SLL
- 5 out of 9 (56%) PRs in patients with r/r FL
- 1 out of 7 (14%) PRs in patients with r/r iNHL (marginal zone lymphoma and Waldenstrom
- A complete response (CR) was seen in the first r/r peripheral T cell lymphoma (PTCL)
patient evaluated in the study
- PRs have been seen in heavily pre-treated patients, including a patient with FL who
relapsed on ibrutinib and a patient with SLL who relapsed on venetoclax, both of whom
remain on drug after 10 months of therapy
Results also showed that cerdulatinib was generally well-tolerated in these heavily pre-treated patients (at target drug levels). However, three patients at 35 mg BID achieved higher than expected drug concentrations and had severe adverse events including two grade 5 infections and one case of grade three pancreatitis. The dose was subsequently reduced to 30 mg BID and a PK monitoring strategy was implemented. This has resulted in an improved safety profile and more consistent PK, while still maintaining clinical activity.
Presenter: Dr Paul Hamlin
Affiliation: Memorial Sloan Kettering Cancer Center, NY, USA
Topic: THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES COMPLETE INHIBITION OF SYK AND JAK AND RAPID TUMOR RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
Abstract S773 will be presented by Paul Hamlin on Sunday, June 25, 08:00 - 09:15 in Hall A.
About the EHA Annual Congress Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma - diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.
CONTACT: Contact: EHA Executive Office, Ineke van der Beek, Jon Tarifa, E-mail: firstname.lastname@example.org, Mobile: +31(0)6-2011-1055